S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
S&P 500   3,310.11 (+1.19%)
DOW   26,659.11 (+0.52%)
QQQ   276.39 (+1.75%)
AAPL   115.32 (+3.71%)
MSFT   204.72 (+1.01%)
FB   280.83 (+4.92%)
GOOGL   1,556.88 (+3.05%)
AMZN   3,211.01 (+1.52%)
TSLA   410.83 (+1.18%)
NVDA   520.96 (+3.14%)
BABA   312.56 (+1.50%)
CGC   18.78 (+2.40%)
GE   7.37 (-0.67%)
MU   50.48 (+0.96%)
AMD   78.02 (+2.12%)
T   26.76 (+0.98%)
F   7.90 (+2.60%)
ACB   4.09 (+6.79%)
GILD   58.53 (-0.32%)
NFLX   504.21 (+3.70%)
NIO   31.99 (+16.28%)
BA   148.29 (+0.10%)
DIS   121.54 (+2.59%)
Log in
NASDAQ:BTAI

BioXcel Therapeutics Stock Forecast, Price & News

$47.05
+1.59 (+3.50 %)
(As of 10/29/2020 12:00 AM ET)
Add
Compare
Today's Range
$45.02
Now: $47.05▼
$47.72
50-Day Range
$41.79
MA: $46.65▼
$54.47
52-Week Range
$3.76
Now: $47.05▼
$71.50
Volume290,043 shs
Average Volume599,583 shs
Market Capitalization$1.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.64
BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence-based drug development in the fields of neuroscience and immuno-oncology in the United States. The company is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies. BioXcel Therapeutics, Inc. has a collaboration with Merck KGaA, Nektar Therapeutics, and Pfizer Inc. to develop a therapy for treating pancreatic cancer. The company was founded in 2017 and is headquartered in New Haven, Connecticut. BioXcel Therapeutics, Inc. is a subsidiary of BioXcel Corporation.
Read More
BioXcel Therapeutics logo

Beat the Market (BTM) Rank™

Analyst Opinion: 4.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.77 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BTAI
Previous Symbol
CUSIPN/A
CIK1720893
Webwww.bioxceltherapeutics.com
Phone475-238-6837
Employees18

Debt

Debt-to-Equity RatioN/A
Current Ratio4.23
Quick Ratio4.23

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.49 per share
Price / Book31.58

Profitability

EPS (Most Recent Fiscal Year)($2.02)
Net Income$-32,970,000.00
Net MarginsN/A
Return on Equity-114.52%
Return on Assets-90.75%

Miscellaneous

Outstanding Shares22,355,000
Market Cap$1.05 billion
Next Earnings Date11/12/2020 (Estimated)
OptionableNot Optionable
$47.05
+1.59 (+3.50 %)
(As of 10/29/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BTAI News and Ratings via Email

Sign-up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BioXcel Therapeutics (NASDAQ:BTAI) Frequently Asked Questions

How has BioXcel Therapeutics' stock price been impacted by COVID-19?

BioXcel Therapeutics' stock was trading at $29.48 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, BTAI stock has increased by 59.6% and is now trading at $47.05.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of BioXcel Therapeutics?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioXcel Therapeutics in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BioXcel Therapeutics.

When is BioXcel Therapeutics' next earnings date?

BioXcel Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020.
View our earnings forecast for BioXcel Therapeutics.

How were BioXcel Therapeutics' earnings last quarter?

BioXcel Therapeutics Inc (NASDAQ:BTAI) issued its quarterly earnings results on Friday, August, 14th. The company reported ($1.06) earnings per share for the quarter, missing the consensus estimate of ($0.74) by $0.32.
View BioXcel Therapeutics' earnings history.

What price target have analysts set for BTAI?

7 equities research analysts have issued twelve-month price targets for BioXcel Therapeutics' shares. Their forecasts range from $24.00 to $175.00. On average, they expect BioXcel Therapeutics' stock price to reach $95.57 in the next twelve months. This suggests a possible upside of 103.1% from the stock's current price.
View analysts' price targets for BioXcel Therapeutics.

Are investors shorting BioXcel Therapeutics?

BioXcel Therapeutics saw a decline in short interest during the month of October. As of October 15th, there was short interest totaling 2,320,000 shares, a decline of 13.8% from the September 30th total of 2,690,000 shares. Based on an average trading volume of 664,000 shares, the short-interest ratio is currently 3.5 days. Currently, 18.3% of the shares of the company are short sold.
View BioXcel Therapeutics' Short Interest.

Who are some of BioXcel Therapeutics' key competitors?

Some companies that are related to BioXcel Therapeutics include Evotec (EVTCY), Reata Pharmaceuticals (RETA), Hutchison China MediTech (HCM), Sage Therapeutics (SAGE), PTC Therapeutics (PTCT), FibroGen (FGEN), ChemoCentryx (CCXI), TG Therapeutics (TGTX), Legend Biotech (LEGN), Deciphera Pharmaceuticals (DCPH), Principia Biopharma (PRNB), MorphoSys (MOR), Schrödinger (SDGR), Global Blood Therapeutics (GBT) and Insmed (INSM).
View all competitors.

What other stocks do shareholders of BioXcel Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioXcel Therapeutics investors own include NVIDIA (NVDA), Alibaba Group (BABA), Crispr Therapeutics (CRSP), JD.com (JD), Inseego (INSG), Marvell Technology Group (MRVL), InVitae (NVTA), Tesla (TSLA), Advanced Micro Devices (AMD) and Editas Medicine (EDIT).

Who are BioXcel Therapeutics' key executives?

BioXcel Therapeutics' management team includes the following people:
  • Dr. Vimal D. Mehta Ph.D., Founder, CEO, Pres, Sec. & Director (Age 58)
  • Dr. Frank D. Yocca Ph.D., Chief Scientific Officer (Age 63)
  • Dr. Vincent J. O'Neill M.D., B.Sc., M.R.C.P., Sr. VP & Chief Medical Officer (Age 50)
  • Mr. Richard I. Steinhart MBA, Chief Financial Officer (Age 62)
  • Mr. Chids Mahadevan, VP of Fin. & Chief Accounting Officer (Age 47)

When did BioXcel Therapeutics IPO?

(BTAI) raised $60 million in an initial public offering (IPO) on Thursday, March 8th 2018. The company issued 5,000,000 shares at a price of $11.00-$13.00 per share. Barclays, UBS Investment Bank and BMO Capital Markets served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is BioXcel Therapeutics' stock symbol?

BioXcel Therapeutics trades on the NASDAQ under the ticker symbol "BTAI."

Who are BioXcel Therapeutics' major shareholders?

BioXcel Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Artemis Investment Management LLP (4.48%), Capital Investment Advisory Services LLC (0.06%), Cambridge Investment Research Advisors Inc. (0.03%) and Pacer Advisors Inc. (0.01%). Company insiders that own BioXcel Therapeutics stock include Frank Yocca, Peter Mueller, Richard I Steinhart and Vimal Mehta.
View institutional ownership trends for BioXcel Therapeutics.

Which major investors are buying BioXcel Therapeutics stock?

BTAI stock was acquired by a variety of institutional investors in the last quarter, including Artemis Investment Management LLP, Cambridge Investment Research Advisors Inc., Pacer Advisors Inc., and Capital Investment Advisory Services LLC. Company insiders that have bought BioXcel Therapeutics stock in the last two years include Frank Yocca, Peter Mueller, Richard I Steinhart, and Vimal Mehta.
View insider buying and selling activity for BioXcel Therapeutics.

How do I buy shares of BioXcel Therapeutics?

Shares of BTAI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BioXcel Therapeutics' stock price today?

One share of BTAI stock can currently be purchased for approximately $47.05.

How big of a company is BioXcel Therapeutics?

BioXcel Therapeutics has a market capitalization of $1.05 billion. The company earns $-32,970,000.00 in net income (profit) each year or ($2.02) on an earnings per share basis. BioXcel Therapeutics employs 18 workers across the globe.

What is BioXcel Therapeutics' official website?

The official website for BioXcel Therapeutics is www.bioxceltherapeutics.com.

How can I contact BioXcel Therapeutics?

BioXcel Therapeutics' mailing address is 555 LONG WHARF DRIVE, NEW HAVEN CT, 06511. The company can be reached via phone at 475-238-6837 or via email at [email protected]

This page was last updated on 10/29/2020 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.